Skip to main content

Table 2 Changes from baseline in ADAS-cog for on-treatment population

From: Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

  3 months 6 months 9 months 12 months 15 months 18 months
5 mg/day 1.43 ± 0.50 2.52 ±0.56 3.02 ± 0.62 5.14 ± 0.75 7.18 ± 0.81 8.96 ± 1.07
(n = 126) (n = 118) (n = 106) (n = 95) (n = 83) (n = 63)
Placebo 1.58 ± 0.44 3.16 ± 0.54 3.99 ± 0.68 6.26 ± 0.69 8.74 ± 0.91 11.63 ± 1.15
(n = 127) (n = 114) (n = 109) (n = 101) (n = 86) (n = 59)
       p = 0.03
  1. Data presented as mean ± standard error.